Literature DB >> 8160706

The G-C specific DNA binding drug, mithramycin, selectively inhibits transcription of the C-MYC and C-HA-RAS genes in regenerating liver.

V W Campbell1, D Davin, S Thomas, D Jones, J Roesel, R Tran-Patterson, C A Mayfield, B Rodu, D M Miller, R A Hiramoto.   

Abstract

Expression of the c-myc and c-Ha-ras protooncogenes is dramatically increased in regenerating rat liver as an early response to partial hepatectomy. Nuclear runon transcription studies confirm that the increased c-myc and c-Ha-ras mRNA levels in regenerating livers reflect transcriptional activation of these genes. Mithramycin, a G-C specific DNA binding drug, prevents the increased transcriptional activity of c-myc and c-Ha-ras genes after hepatectomy but does not alter the transcriptional activity of the beta-actin gene. Continuous exposure of rats to mithramycin after hepatectomy prevents the increase in both c-myc and c-Ha-ras expression and blocks the increased cellular proliferation characteristic of regeneration. The delayed increase in c-myc and c-Ha-ras gene expression is associated with a delay in cellular proliferation. The inhibition of c-myc and c-Ha-ras transcription by mithramycin, the delay in cellular proliferation, and the ability of mithramycin to prevent protein binding to the c-myc promoter, suggest that the increased expression of these genes is a necessary component of liver regeneration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160706     DOI: 10.1097/00000441-199403000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  12 in total

1.  Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin.

Authors:  N Sandorfi; N Louneva; E Hitraya; G Hajnoczky; B Saitta; S A Jimenez
Journal:  Ann Rheum Dis       Date:  2005-05-18       Impact factor: 19.103

2.  The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis.

Authors:  Jean-Philippe Brouland; Pascal Gélébart; Tünde Kovàcs; Jocelyne Enouf; Johannes Grossmann; Béla Papp
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

3.  Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.

Authors:  Janina Seznec; Björn Silkenstedt; Ulrike Naumann
Journal:  J Neurooncol       Date:  2010-06-17       Impact factor: 4.130

4.  DDB2 induces nuclear accumulation of the hepatitis B virus X protein independently of binding to DDB1.

Authors:  A Nag; A Datta; K Yoo; D Bhattacharyya; A Chakrabortty; X Wang; B L Slagle; R H Costa; P Raychaudhuri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Dimerization and DNA recognition rules of mithramycin and its analogues.

Authors:  Stevi Weidenbach; Caixia Hou; Jhong-Min Chen; Oleg V Tsodikov; Jürgen Rohr
Journal:  J Inorg Biochem       Date:  2015-12-18       Impact factor: 4.155

6.  A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis.

Authors:  Luz E Núñez; Stephen E Nybo; Javier González-Sabín; María Pérez; Nuria Menéndez; Alfredo F Braña; Khaled A Shaaban; Min He; Francisco Morís; José A Salas; Jürgen Rohr; Carmen Méndez
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

7.  Spermine attenuates the action of the DNA intercalator, actinomycin D, on DNA binding and the inhibition of transcription and DNA replication.

Authors:  Sheng-Yu Wang; Alan Yueh-Luen Lee; Yueh-Luen Lee; Yi-Hua Lai; Jeremy J W Chen; Wen-Lin Wu; Jeu-Ming P Yuann; Wang-Lin Su; Show-Mei Chuang; Ming-Hon Hou
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

8.  Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia.

Authors:  Lorenzo Capretto; Stefania Mazzitelli; Eleonora Brognara; Ilaria Lampronti; Dario Carugo; Martyn Hill; Xunli Zhang; Roberto Gambari; Claudio Nastruzzi
Journal:  Int J Nanomedicine       Date:  2012-01-18

9.  Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder.

Authors:  Amrita Banerjee; Sulagna Sanyal; Kirti K Kulkarni; Kuladip Jana; Siddhartha Roy; Chandrima Das; Dipak Dasgupta
Journal:  FEBS Open Bio       Date:  2014-10-16       Impact factor: 2.693

10.  The crucial role of divalent metal ions in the DNA-acting efficacy and inhibition of the transcription of dimeric chromomycin A3.

Authors:  Chun-Wei Hsu; Show-Mei Chuang; Wen-Ling Wu; Ming-Hon Hou
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.